Opko Health, Inc
OPKO Health is a U.S.-based biopharmaceutical and diagnostics company with operations spanning pharmaceutical development, commercial products, laboratory testing, and product licensing. Its business includes international pharmaceutical platforms, a U.S. diagnostics laboratory business through BioReference, and partnerships that generate royalties, milestones, and other intellectual property-related revenue.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical, specialty, women’s health, and urology testing offered through BioReference.
Marketed drug products and related international pharmaceutical operations.
Revenue from intellectual property, partner royalties, and contract milestones.
Research-stage assets, collaborations, and other non-core revenue items.
Products
Reported · share of revenue- Services61.0 %
- Products25.9 %
- Transfer of Intellectual Property and Other13.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
OPKO sells to physicians, hospitals, clinics, geneticists, correctional health facilities, and other healthcare providers that order diagnostic tests for patient care. On the pharmaceutical side, its customers and counterparties include patients, healthcare providers, distributors, and commercial partners that license or commercialize its products and intellectual property.
Order diagnostic tests such as 4Kscore and specialty lab panels to support diagnosis and treatment decisions.
Use laboratory services for clinical chemistry, pathology, and women’s health testing.
Influence reimbursement and network access for laboratory testing services.
License OPKO’s assets, pay royalties, and fund development or commercialization milestones.
Ultimately receive the diagnostic and therapeutic benefit from tests and medicines, though purchasing is usually mediated by providers and payors.
Strategy
OPKO’s strategy centers on combining diagnostics, commercial pharmaceuticals, and partner-driven intellectual property revenue to diversify its business base. It also relies on international pharmaceutical platforms and collaborations to extend the reach of products such as Somatrogon while using BioReference to maintain a U.S. diagnostics franchise.
Specialty tests can deepen physician relationships and support differentiated lab volumes.
Royalties and milestones provide non-lab revenue tied to external commercialization success.
Foreign operating platforms broaden product access and create commercial scale outside the U.S.
Pipeline progress can create future product revenue and licensing opportunities.
Geography
Q1/2026OPKO has a U.S. diagnostics footprint, with BioReference serving physicians and facilities nationwide and women’s health and clinical testing concentrated in New York and New Jersey. Its pharmaceutical operations are international, with principal platforms in Spain, Ireland, Chile, and Mexico, and research and development facilities in the United States, Ireland, Israel, and Spain.
Share of the revenue the company reports by geography.
Risks
OPKO faces reimbursement pressure, competitive intensity, and regulatory risk across both diagnostics and pharmaceuticals. Its business also depends on successful product development, partner commercialization, patent protection, and the performance of international operations, which adds foreign exchange and impairment risk.
- Reimbursement pressure and payor consolidationImpact: HighLikelihood: High
Large insurers can demand lower fees, narrower networks, or risk-sharing terms for lab services.
Exposure: BioReference and clinical testing
- Quality and laboratory performance riskImpact: HighLikelihood: Medium
Errors in testing can lead to patient harm, lawsuits, reputational damage, and regulatory scrutiny.
Exposure: Diagnostics operations
- Regulatory and approval riskImpact: HighLikelihood: Medium
Product development depends on FDA and other regulatory approvals and ongoing compliance.
Exposure: Pipeline and marketed products
- Impairment risk on goodwill and intangiblesImpact: HighLikelihood: Medium
Large acquired intangible balances depend on future cash flow assumptions and product performance.
Exposure - Competitive pressureImpact: MediumLikelihood: High
Larger pharma and diagnostics peers have greater resources, scale, and commercialization reach.
Exposure: Both pharmaceuticals and diagnostics
- Foreign exchange and international operating riskImpact: MediumLikelihood: Low
International subsidiaries and foreign-currency exposure can affect reported revenue and cost of sales.
Exposure
Accounting
Judgemental itemsDifferent contract types can recognize revenue at different times, affecting quarter-to-quarter comparability.
Impact: BARDA contract revenue, NGENLA royalties, and commercial milestones
Large acquired balances are tested against future cash flows and can produce material write-downs if assumptions weaken.
Impact: Diagnostics goodwill, Ireland reporting unit goodwill, IPR&D
International subsidiaries and foreign-currency-denominated costs can move reported revenue and margins.
Impact: Chile, Mexico, Spain, and Ireland operations
Some commitments are contingent or uncapped, making liabilities and future cash needs harder to estimate.
Impact: Contractual obligations and royalty agreements
Similar listed companies
Publicly listed companies with a comparable business focus.
Upstream Bio, Inc.
UPB · Pharmaceutical Preparations
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
PERRIGO Co plc
PRGO · Pharmaceutical Preparations
Perrigo Co plc is a consumer self-care company focused on over-the-counter health and wellness products sold through retail and pharmacy channels.
Cosmos Health Inc.
COSM · Wholesale-Drugs, Proprietaries & Druggists' Sundries
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
Oklo Inc.
OKLO · Electric Services
Last updated: 24/09/2026